Management of Antithrombotic Therapy for Gastroenterological Endoscopy from a Cardio-Cerebrovascular Physician's Point of View
- Authors
- Oh, Hyung-Geun
- Issue Date
- Jul-2014
- Publisher
- 대한소화기내시경학회
- Keywords
- Endoscopy; Antithrombotics; Hemorrhage; Thromboembolism
- Citation
- Clinical Endoscopy, v.47, no.4, pp 320 - 323
- Pages
- 4
- Journal Title
- Clinical Endoscopy
- Volume
- 47
- Number
- 4
- Start Page
- 320
- End Page
- 323
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12081
- DOI
- 10.5946/ce.2014.47.4.320
- ISSN
- 2234-2400
2234-2443
- Abstract
- Periprocedural management of antithrombotics for gastroenterological endoscopy is a common clinical issue. To decide how to manage the use of antithrombotics in patients undergoing endoscopy, the risk for hemorrhage and thromboembolism during the procedure must be considered. For low-risk procedures, no adjustments in antithrombotics are needed. For high-risk procedures with a low thromboembolic risk, discontinuation of warfarin at 5 days, and clopidogrel at 5 to 7 days before the procedure has been recommended. However, it is better to continue aspirin use even during high-risk procedures. A heparin bridging therapy may be considered before endoscopy in patients with a high thromboembolic risk. The management of patients taking antithrombotics remains complex, especially in high-risk settings.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.